Efficacy of Immunotherapy Combined with Antiangiogenic Therapy in Treatment-Failure Patients with Advanced Carcinoma Ex Pleomorphic Adenoma of the Submandibular Gland: A Case Report

被引:0
作者
Sa, Huanlan [1 ]
Xu, Yinghui [1 ]
Ma, Xiaobo [2 ]
Wang, Xu [1 ]
Sun, Chao [1 ]
Qiu, Shi [1 ]
Guo, Ye [1 ]
Yang, Zhiguang [3 ]
Liu, Yunpeng [3 ]
Ma, Kewei [1 ]
机构
[1] First Hosp Jilin Univ, Canc Ctr, Changchun 130021, Peoples R China
[2] First Hosp Jilin Univ, Pathol Dept, Changchun 130021, Peoples R China
[3] First Hosp Jilin Univ, Dept Thorac Surg, Changchun 130021, Peoples R China
关键词
carcinoma ex pleomorphic adenoma; submandibular gland; immunotherapy; antiangiogenic therapy; PROGRAMMED DEATH LIGAND-1; SINTILIMAB PLUS ANLOTINIB; PHASE-II; SALIVARY-GLANDS; RECURRENT; PEMBROLIZUMAB;
D O I
10.3390/curroncol29090498
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Carcinoma ex pleomorphic adenoma (Ca ex PA) is a rare malignant tumor that arises from a primary or recurrent benign pleomorphic adenoma (PA). Ca ex PA has an aggressive behavior and poor prognosis. To date, there are no standardized therapeutic methods. Herein, we reported a case of a 57-year-old Chinese female with Ca ex PA of the submandibular gland. After surgery, cervical lymph nodes recurred, and multiple distant metastases were detected. During the treatment, she received multiple chemotherapies and radiotherapy but suffered from multidrug resistance and repeated disease progression. Hence, PD-1 inhibitor (sintilimab), in combination with anlotinib, was administered, which resulted in better control of pulmonary metastases compared to the other treatment regimens. This provided an alternative treatment option for Ca ex PA of the submandibular gland patients with failed multiple therapies.
引用
收藏
页码:6334 / 6341
页数:8
相关论文
共 33 条
  • [1] [Anonymous], LENV PEMBR PEOPL ADV
  • [2] Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas
    Arolt, Christoph
    Meyer, Moritz
    Ruesseler, Vanessa
    Nachtsheim, Lisa
    Wuerdemann, Nora
    Dreyer, Thomas
    Gattenloehner, Stefan
    Wittekindt, Claus
    Buettner, Reinhard
    Quaas, Alexander
    Klussmann, Jens Peter
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (07) : 1363 - 1373
  • [3] A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC
    Chau, N. G.
    Hotte, S. J.
    Chen, E. X.
    Chin, S. F.
    Turner, S.
    Wang, L.
    Siu, L. L.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (06) : 1562 - 1570
  • [4] Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC
    Chu, Tianqing
    Zhong, Runbo
    Zhong, Hua
    Zhang, Bo
    Zhang, Wei
    Shi, Chunlei
    Qian, Jialin
    Zhang, Yanwei
    Chang, Qing
    Zhang, Xueyan
    Dong, Yu
    Teng, Jiajun
    Gao, Zhiqiang
    Qiang, Huiping
    Nie, Wei
    Zhao, Yiming
    Han, Yuchen
    Chen, Ya
    Han, Baohui
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : 643 - 652
  • [5] Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma Findings of the Phase 1b KEYNOTE-028 Study
    Cohen, Roger B.
    Delord, Jean-Pierre
    Doi, Toshihiko
    Piha-Paul, Sarina A.
    Liu, Stephen V.
    Gilbert, Jill
    Algazi, Alain P.
    Damian, Silvia
    Hong, Ruey-Long
    Le Tourneau, Christophe
    Day, Daphne
    Varga, Andrea
    Elez, Elena
    Wallmark, John
    Saraf, Sanatan
    Thanigaimani, Pradeep
    Cheng, Jonathan
    Keam, Bhumsuk
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (11): : 1083 - 1088
  • [6] Carcinoma Ex Pleomorphic Adenoma, with Particular Emphasis on Early Lesions
    Di Palma S.
    [J]. Head and Neck Pathology, 2013, 7 (Suppl 1) : 68 - 76
  • [7] CD31, a Valuable Marker to Identify Early and Late Stages of T Cell Differentiation in the Human Thymus
    Douaisi, Marc
    Resop, Rachel S.
    Nagasawa, Maho
    Craft, Joshua
    Jamieson, Beth D.
    Blom, Bianca
    Uittenbogaart, Christel H.
    [J]. JOURNAL OF IMMUNOLOGY, 2017, 198 (06) : 2310 - 2319
  • [8] Vascular endothelial growth factor immunoexpression is increased in malignant salivary gland tumors
    Fonseca, Felipe Paiva
    Montanhana Basso, Marcos Paulo
    Mariano, Fernanda Viviane
    Kowalski, Luiz Paulo
    Lopes, Marcio Ajudarte
    Martins, Manoela Domingues
    Carrinho Ayroza Rangel, Ana Lucia
    Santos-Silva, Alan Roger
    Vargas, Pablo Agustin
    [J]. ANNALS OF DIAGNOSTIC PATHOLOGY, 2015, 19 (03) : 169 - 174
  • [9] Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
    Fuchs, Charles S.
    Doi, Toshihiko
    Jang, Raymond W.
    Muro, Kei
    Satoh, Taroh
    Machado, Manuela
    Sun, Weijing
    Jalal, Shadia I.
    Shah, Manish A.
    Metges, Jean-Phillipe
    Garrido, Marcelo
    Golan, Talia
    Mandala, Mario
    Wainberg, Zev A.
    Catenacci, Daniel V.
    Ohtsu, Atsushi
    Shitara, Kohei
    Geva, Ravit
    Bleeker, Jonathan
    Ko, Andrew H.
    Ku, Geoffrey
    Philip, Philip
    Enzinger, Peter C.
    Bang, Yung-Jue
    Levitan, Diane
    Wang, Jiangdian
    Rosales, Minori
    Dalal, Rita P.
    Yoon, Harry H.
    [J]. JAMA ONCOLOGY, 2018, 4 (05)
  • [10] GNEPP DR, 1993, PATHOL ANNU, V28, P279